Latest Breaking News On - Basilea pharmaceutica ltd - Page 4 : comparemela.com

Continued strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to Basilea

Allschwil, Switzerland, March 11, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that the continued strong sales performance of the antifungal Cresemba® (isavuconazole) by its license partner Pfizer Inc. in the Asia Pacific region and China exceeded the sales threshold triggering a USD 1.25 million milestone payment. David Veitch, Basilea’s

United statesSwitzerland generalBasel stadtDavid veitchAsia pacificNils schrIsavuconazole cresembaSwiss exchangePfizer incHead of corporate communications investor relationsBasilea pharmaceutica ltdEuropean unionPharmaceutica ltdChief executive officerCorporate communicationsPublic assessment report

Basilea Pharmaceutica AG: Basilea reports strong 2023 full-year results with profitability significantly above guidance, whilst substantially expanding the R&D portfolio

Basilea Pharmaceutica AG: Basilea reports strong 2023 full-year results with profitability significantly above guidance, whilst substantially expanding the R&D portfolio
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Basel stadtSwitzerland generalDavid veitchAdesh kaulNils schrBiomedical advanced researchBasilea pharmaceutica international ltdAdministration for strategic preparednessHuman servicesBasilea pharmaceutica ltdSwiss exchangeUs department of healthDevelopment authorityHead of corporate communications investor relationsPharmaceutica ltdChief executive officer

Basilea reports strong 2023 full-year results with profitability significantly above guidance, whilst substantially expanding the R&D portfolio

Basilea reports strong 2023 full-year results with profitability significantly above guidance, whilst substantially expanding the R&D portfolio
finanzen.at - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanzen.at Daily Mail and Mail on Sunday newspapers.

Switzerland generalBasel stadtAdesh kaulDavid veitchNils schrSwiss exchangeDevelopment authorityUs department of healthHead of corporate communications investor relationsHuman servicesBasilea pharmaceutica ltdAdministration for strategic preparednessBasilea pharmaceutica international ltdBiomedical advanced researchPharmaceutica ltdChief executive officer

Basilea reports strong 2023 full-year results with

Increased Cresemba® and Zevtera®-related revenue of CHF 150.3 million (+22.9% year-on-year) at upper end of guidanceOperating profit of CHF 19.2 million.

Switzerland generalBasel stadtAdesh kaulNils schrDavid veitchHead of corporate communications investor relationsBiomedical advanced researchHuman servicesUs department of healthBasilea pharmaceutica ltdBasilea pharmaceutica international ltdDevelopment authorityAdministration for strategic preparednessSwiss exchangePharmaceutica ltdChief executive officer

Adhoc: Spexis AG: Spexis announces closing of sale of preclinical antibiotics program to Basilea

Adhoc: Spexis AG: Spexis announces closing of sale of preclinical antibiotics program to Basilea
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Basel stadtSwitzerland generalStephen jasperCanton basel landschaftStefan klotterStephan feldhausBiomedical advanced researchBasilea pharmaceutica ltdUs department of healthGilmartin groupDistrict courtGermany federal ministry of educationNews serviceAdministration for strategic preparednessWorld health organizationHuman services